Exelixis (EXEL) Bɛn Dɛŋɛn Akɔc
AI forecast: EXEL
AI ekek aŋok wɛlɛɛl bɛn bɛn lɔŋɔŋ, bɛn bɛn cɔlɔŋ, kɛ bɛn bɛn cɔlɔŋ. Cɔkɔkɔkɔ cɔlɔŋ bɛn bɛn lɔŋɔŋ. Aŋok wɛlɛɛl aŋok wɛlɛɛl, aŋok wɛlɛɛl aŋok wɛlɛɛl.
Bɛn cɔk ɛcɔk 6
Premium shows the AI's price targets for 1 day, 1 week and 1 month for this and every other stock.
Unlock Premium🔒 Nyɛn cɔk aya bɛn
Ditëëk ë bɛ̈ɛ̈r ë cë lɔ – ditëëk ë cë lɔ kee aköl aköl ë bɛ̈ɛ̈r ë cë lɔ – aye Premium.
Unlock PremiumBɛn kɔc ke bɛn
Exelixis, Inc. is a biotechnology company specializing in the development of promising small-molecule drugs for the treatment of cancer and other serious diseases, including kidney disease, thyroid cancer, and advanced melanoma. The company also establishes strategic partnerships with other pharmaceutical and biotechnology firms.